Classical Hodgkin Lymphoma

CHICAGO — The addition of nivolumab vs. brentuximab vedotin to AVD chemotherapy significantly reduced the risk for disease progression and disease-related death among adults with previously untreated advanced classic Hodgkin lymphoma.

NEW ORLEANS — The addition of brentuximab vedotin and nivolumab to doxorubicin and dacarbazine appeared active among patients with advanced-stage classical Hodgkin lymphoma, according to study results.

Patients with early-stage classic Hodgkin lymphoma and other neoplasms exhibited higher risk for cardiovascular disease-associated mortality compared with cancer-associated mortality later in life, according to study results.

CHICAGO — The addition of brentuximab vedotin to frontline chemotherapy significantly extended OS among patients with advanced classical Hodgkin lymphoma, according to study results presented at ASCO Annual Meeting.

The addition of brentuximab vedotin to front-line chemotherapy reduced risk for death by 41% among patients with newly diagnosed advanced classical Hodgkin lymphoma, according to topline data released by the agent’s manufacturer.

Pembrolizumab followed by doxorubicin, vinblastine and dacarbazine appeared safe and effective for newly diagnosed classical Hodgkin lymphoma, including for patients with bulky disease, according to phase 2 study results published in Blood.

The FDA expanded the approval of pembrolizumab for treatment of classical Hodgkin lymphoma, according to the agent’s manufacturer.

HIV status did not affect outcomes after first-line chemotherapy for patients with advanced classical Hodgkin lymphoma, according to study results presented at Society of Hematologic Oncology Annual Meeting.

The FDA granted priority review to pembrolizumab for the second-line treatment of patients with relapsed or refractory classical Hodgkin lymphoma, according to a press release from the agent’s manufacturer.

Pembrolizumab significantly improved PFS vs. brentuximab vedotin among patients with relapsed or refractory classical Hodgkin lymphoma, according to study results presented at the virtual European Hematology Association Annual Congress.